David B Clause, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4015 I 49 S Service Rd, Opelousas, LA 70570 Phone: 337-942-6503 Fax: 337-942-8831 |
Mr. Thomas Reed Butaud, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4015 Hwy I 49 South Service Rd, Opelousas, LA 70570 Phone: 337-942-6503 Fax: 337-942-8831 |
Mr. Gary L Porubsky, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4015 Hwy I-49 South Service Rd, Opelousas, LA 70570 Phone: 337-942-6503 Fax: 337-942-8831 |
Dr. George Raymond Williams, M.D. Orthopaedic Surgery - Orthopaedic Trauma Medicare: Accepting Medicare Assignments Practice Location: 1233 Wayne Gilmore Circle, Suite 250-a, Opelousas, LA 70570 Phone: 337-948-8556 Fax: 337-948-6881 |
News Archive
A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows that having a sleep disturbance is associated with clinically meaningful reductions in health-related quality of life, and the magnitude of this effect varies by race and sleep disorder.
A recent analysis of published studies examined the clinical consequences of medication adherence. The British Journal of Clinical Pharmacology analysis found that medication adherence is linked with lower risks of needing to be hospitalized and of dying early.
Now, a new study by researchers at the University of California San Francisco and published on the preprint server bioRxiv* in June 2020 shows the effect of phosphorylation on the state and function of the N protein.
Two common procedures to treat pelvic organ prolapse without vaginal mesh are comparable in safety and efficacy, according to research published in the latest issue of the Journal of the American Medical Association. Researchers also found that behavioral and pelvic floor muscle therapy (BPMT) did not improve urinary incontinence or prolapse symptoms in affected women.
NextWave Pharmaceuticals and Tris Pharma, both privately held companies, announced a new collaboration agreement to enhance NextWave's CNS product portfolio utilizing Tris Pharma's unique drug delivery technology for liquid and solid formulations. Tris has reacquired the rights to non CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.
› Verified 8 days ago